Drug Trial Radar · NCT07204236
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion
Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Actual
Start
Jan 18, 2024
Primary completion
Mar 1, 2025
Study completion Mar 1, 2026
Sponsor
- Lead sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg≤20 IU/mL, or HBsAg negative and no seroconversion through an investigator-initiated clinical study.
Conditions
- Chronic Hepatitis B
Interventions
TVAX-008Drug
TVAX-008
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HBSAb levels after end of treatmentTime frame: week24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Province Public Health Clinical Center
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.